Amyloid beta(Aβ)plaques are one of the hallmarks of Alzheimer’s disease(AD).However,currently available anti-amyloid therapies fail to show effectiveness in the treatment of AD in humans.It has been found that there...Amyloid beta(Aβ)plaques are one of the hallmarks of Alzheimer’s disease(AD).However,currently available anti-amyloid therapies fail to show effectiveness in the treatment of AD in humans.It has been found that there are different types of Aβplaque(diffuse and focal types)in the postmortem human brain.In this study,we aimed to investigate the correlations among different types of Aβplaque and AD-related neuropathological and cognitive changes based on a postmortem human brain bank in China.The results indicated that focal plaques,but not diffuse plaques,significantly increased with age in the human hippocampus.We also found that the number of focal plaques was positively correlated with the severity of AD-related neuropathological changes(measured by the“ABC”scoring system)and cognitive decline(measured by the Everyday Cognitive Insider Questionnaire).Furthermore,most of the focal plaques were co-localized with neuritic plaques(identified by Bielschowsky silver staining)and accompanied by microglial and other inflammatory cells.Our findings suggest the potential of using focal-type but not general Aβplaques as biomarkers for the neuropathological evaluation of AD.展开更多
文摘目的系统评价埃克替尼治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的不同组织病理学类型与ECOG评分差异的临床有效性。方法收集国内外埃克替尼治疗NSCLC的临床治疗性试验研究数据,用Revman5.2进行meta分析。结果腺癌vs鳞癌纳入了8篇研究,固定效应M-H分析合并效应优势比OR=2.46,P=0.0005;ECOG评分:0~1 vs 2~4和0~2 vs 3~4 2个亚组分别纳入研究6篇和3篇,均存在异质性,随机效应M-H分析合并效应分别是RR=1.20,P=0.15和RR=1.77,P=0.09。结论埃克替尼治疗NSCLC的有效性腺癌比鳞癌更敏感;ECOG评分高低不影响治疗的有效性,但仍可扩大研究样本进行分析。
基金This work was supported by grants from the National Natural Science Foundation of China(81771205 and 81801114)the CAMS Innovation Fund for Medical Sciences(2021-I2M-1-025)Science Innovation 2030–Brain Science and BrainInspired Intelligence Technology Major Project(2021ZD0201100 and 2021ZD0201101).We thank Dr.Xiaojin Qian and Dr.Yongmei Chen(Department of Anatomy,Histology and Embryology,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences)for technical assistance in immunohistochemistry.
文摘Amyloid beta(Aβ)plaques are one of the hallmarks of Alzheimer’s disease(AD).However,currently available anti-amyloid therapies fail to show effectiveness in the treatment of AD in humans.It has been found that there are different types of Aβplaque(diffuse and focal types)in the postmortem human brain.In this study,we aimed to investigate the correlations among different types of Aβplaque and AD-related neuropathological and cognitive changes based on a postmortem human brain bank in China.The results indicated that focal plaques,but not diffuse plaques,significantly increased with age in the human hippocampus.We also found that the number of focal plaques was positively correlated with the severity of AD-related neuropathological changes(measured by the“ABC”scoring system)and cognitive decline(measured by the Everyday Cognitive Insider Questionnaire).Furthermore,most of the focal plaques were co-localized with neuritic plaques(identified by Bielschowsky silver staining)and accompanied by microglial and other inflammatory cells.Our findings suggest the potential of using focal-type but not general Aβplaques as biomarkers for the neuropathological evaluation of AD.
